KRAS and non-small cell lung carcinoma: Sotorasib (Lumakras/Lumykras, Amgen, Inc., Thousand Oaks, CA, USA) was the first (2021) compound approved by both the FDA and EMA (based on CodeBreaK 100 clinical trial NCT03600883) for treating KRAS-mutated (G12C) locally advanced or metastatic non-small cell lung cancer (NSCLC) [24,25].